SINGAPORE, Feb. 28, 2026 - MetaOptics Ltd, which made its debut on the Catalist board of the Singapore Exchange (SGX-ST) in September 2025, has announced impressive financial results for the fiscal year ending December 31, 2025. The company reported a staggering 891% increase in revenue, reaching S$787,388, up from S$79,440 in the previous year. This remarkable growth underscores MetaOptics' robust position in the metalens technology sector.
Key Financial Metrics Highlight Growth Trajectory
The financial results reveal a significant leap in revenue driven primarily by a successful delivery of a direct laser writer to a customer in Taiwan. This strategic move has enabled the prototyping and fabrication of metalenses within the region's semiconductor supply chain. Additionally, the company has experienced heightened global sales of metalenses and modules, which facilitate customer evaluations and integrations into their applications. Learn more on Investopedia.
Despite the impressive revenue growth, MetaOptics reported a net loss of S$5.4 million for FY2025, an increase from the S$1.95 million loss recorded in the previous year. The loss per share attributable to equity holders rose to 2.54 cents from 1.01 cents. The increase in losses can be attributed to several factors, including substantial one-off professional fees amounting to approximately S$2.4 million related to its SGX listing and a proposed dual listing on the NASDAQ, announced on November 17, 2025.
Investment in Growth and Development
MetaOptics is committed to positioning itself for future growth, as evidenced by its investment in research and development (R&D). The company incurred approximately S$1.8 million in R&D expenses in FY2025, focusing on launching new products, including proprietary metalens-powered consumer electronics prototypes showcased at CES 2026. The positive customer feedback from these launches indicates a promising trajectory for the company's future offerings.
Furthermore, the company recorded about S$1 million in non-cash expenses, which included finance expenses, depreciation, and amortization. These financial dynamics highlight MetaOptics' ongoing efforts to innovate and enhance its product lineup, even as it navigates through initial losses.
Leadership Changes to Drive Strategic Initiatives
In alignment with its growth strategy, MetaOptics has appointed Aloysius Chua Hao Peng as Executive Director and Chief Executive Officer. Aloysius is expected to spearhead strategic initiatives across the company's four business groups, which include Metalens Equipment, Metalens Foundry, Metalens Modules, and Metalens Solutions. This leadership change is seen as a critical step in enhancing operational effectiveness and driving the company's expansion efforts.
The Metalens Equipment group is focused on selling advanced metalens production machines, such as direct laser writers and automatic testers, while the Metalens Foundry group specializes in manufacturing customized metalenses, particularly in the United States. This strategic base will enable MetaOptics to cater to prestigious clients across various sectors, including 5G smartphones, data communications, and data centers.
Looking Ahead: Strengthening Competitive Position
MetaOptics' strong cash position, with S$8.8 million on hand, indicates its capability to fund future growth initiatives and withstand initial financial setbacks. The company's commitment to innovation and expansion into new markets is likely to bolster its competitive edge in the rapidly evolving tech landscape. As it continues to enhance its product offerings and customer relationships, MetaOptics is poised to capture more opportunities within the burgeoning metalens industry.
With a clear vision and strategic leadership under Aloysius Chua, MetaOptics aims to leverage its recent successes and prepare for further advancements in the sector. The company's focus on customer-driven solutions and cutting-edge technology positions it well for sustained growth in the coming years.
Originally reported by Pr Newswire Apac. View original.